Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Track-and-Trace Bill Clears House With New Electronic Labeling Language

This article was originally published in The Pink Sheet Daily

Executive Summary

Safeguarding America’s Pharmaceuticals Act passes on suspension calendar, but likely sets up fight with Senate in conference.

You may also be interested in...



FDA’s Pharmaceutical Regulatory Workload Picks Up In 2013 After Slow 2012

Congress likely to release $85 million in drug user fees that were taken out of the agency’s fiscal 2013 appropriations by sequestration, but it won’t boost FDA’s overall budget.

Track-And-Trace Insufficient For Biosimilar Pharmacovigilance, Brand Companies Say

A Johnson & Johnson citizen petition lays out the company’s case for individual non-proprietary names for biologics and each of their biosimilars, citing the risk of inappropriate substitution.

Compounding Deal In Congress Allows Voluntary FDA Oversight Of Large-Scale Facilities

Compounders could submit to inspections, user fees and adverse event reporting, providing potential market advantage; Legislation, which includes track and trace draft bill, avoids compounding controversies and could be poised for swift passage.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075909

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel